Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.
This activity is supported by educational grants from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.
Release Date: August 13, 2018
Expiration Date: August 13, 2019
Media: Internet - based
Instructions for This Activity and Receiving Credit
This educational activity is directed toward medical oncologists. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of cSCC are also invited to participate, as well as those involved in the multidisciplinary care of patients with cSCC, including dermatologists, surgeons, head and neck cancer surgeons, and Mohs surgeons.
At the conclusion of this activity, you should be better prepared to:
Omid Hamid, MD
Chief, Translational Research & Immuno-Oncology
Director, Cutaneous Malignancies
The Angeles Clinic and Research Institute
Director, Experimental Therapeutics
Cedars-Sinai Medical Care Foundation
Los Angeles, CA
Disclosure: Consultant: Amgen, Novartis, Roche, BMS, Merck; Speakers’ Bureau: BMS, Genentech, Novartis, Amgen; Contracted Research for Institution: AstraZeneca, BMS, Celldex, Genentech, Immunocore, Incyte, Merck, Merck-Serono, MedImmune, Novartis, Pfizer, Rinat, Roche
Jason J. Luke, MD, FACP
Assistant Professor of Medicine
The University of Chicago Medicine
Disclosure: Grant/Research Support: AbbVie, Array, Boston Biomedical, Bristol-Myers Squibb, Celldex, CheckMate, Corvus, Delcath, Five Prime, Genentech, lmmunocore, lncyte, Medlmmune, Macrogenics, Novartis, Pharmacyclics, Palleon, Merck, Tesaro, Xencor; Consultant: 7 Hills, Actym, Amgen, Array, AstraZeneca, BeneVir, Bristol-Myers Squibb, Castle, Check-Mate, Compugen, EMO Serono, Gilead, Janssen, Merck, NewLink, Nimbus, Novartis, Palleon, RefleXion, Syndax, Tempest, WntRx; Travel: Amgen, Array, AstraZeneca, BeneVir, Bristol-Myers Squibb, Castle, CheckMate, EMD Serono, Gilead, Janssen, Merck, NewLink, Novartis, RefleXion
Nikhil I. Khushalani, MD
Vice Chair, Department of Cutaneous Oncology
Moffitt Cancer Center
Disclosure: Research Funding (Institute): BMS, Merck, Amgen, GSK, Novartis, Regeneron, HUYA; Advisory Board: Castle Biosciences, BMS, EMD Serono, Genentech, Regeneron; Data Safety Monitoring Board: AstraZeneca
Chrysalyne Schmults, MD, MSCE
Associate Professor of Dermatology
Harvard Medical School
Director, Dermatologic Surgery Center
Brigham and Women’s Hospital
Disclosure: Grant/Research Support: Site PI, Regeneron EMPOWER-CSCC Trial
The staff of Physicians' Education Resource®, LLC have no relevant financial relationships with commercial interests to disclose.
As a sponsor accredited by the ACCME, it is the policy of Physicians’ Education Resource®, LLC, (PER®) to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines relevant financial relationships as financial relationships in any amount occurring within the past 12 months that creates a conflict of interest (COI).
Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.
This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.
Dec 31, 2018
Medical Crossfire®: Defining New Roles for the Application of PARP Inhibition Strategies in Multiple Tumor Types
Dec 31, 2018
Dec 31, 2018